These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21787206)

  • 1. Ustekinumab for the treatment of HIV psoriasis.
    Paparizos V; Rallis E; Kirsten L; Kyriakis K
    J Dermatolog Treat; 2012 Dec; 23(6):398-9. PubMed ID: 21787206
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.
    Wang DM; Fernandez AP; Calabrese CM; Calabrese LH
    Clin Exp Dermatol; 2019 Jan; 44(1):113-115. PubMed ID: 29797733
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of severely itchy scalp psoriasis and palmoplantar pustulosis with unsatisfied response to secukinumab, adalimumab or ustekinumab using upadacitinib: A report of two cases.
    Hu W; Wang Y; Zhang S; Wu X; Lian C
    J Dermatol; 2024 May; 51(5):e151-e153. PubMed ID: 38031884
    [No Abstract]   [Full Text] [Related]  

  • 4. Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two Greek patients from the psoriasis hospital-based clinic.
    Papadavid E; Ferra D; Koumaki D; Dalamaga M; Stamou C; Theodoropoulos K; Rigopoulos D
    Dermatology; 2014; 228(2):107-11. PubMed ID: 24504077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection.
    Saeki H; Ito T; Hayashi M; Fukuchi O; Umezawa Y; Nobeyama Y; Teruya K; Nakagawa H
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1653-5. PubMed ID: 24754476
    [No Abstract]   [Full Text] [Related]  

  • 6. Recalcitrant psoriasis responding to new bilogic drug: ustekinumab.
    Husein-ElAhmed H; Molina-Leyva A; Garrido-TorresPuchol V; Ruiz-Carrascosa J
    Ann Saudi Med; 2013; 33(6):632-3. PubMed ID: 24413873
    [No Abstract]   [Full Text] [Related]  

  • 7. Good efficacy and tolerability of ustekinumab in a patient with severe psoriasis under haemodialysis.
    Larquey M; Poreaux C; Cuny JF; Barbaud A; Schmutz JL
    Eur J Dermatol; 2014; 24(5):618-9. PubMed ID: 25445092
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis Duhring.
    Gkalpakiotis S; Arenberger P; Sticova E; Sefrnova P; Arenbergerova M
    J Dermatol; 2012 Dec; 39(12):1074-5. PubMed ID: 22784106
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy.
    Gutiérrez-González E; Batalla A; de la Mano D
    Dermatol Online J; 2014 Apr; 20(4):22338. PubMed ID: 24746301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ustekinumab in a patient with chronic renal failure on hemodialysis.
    de Unamuno Bustos B; Sánchez RB; Martínez VO; Carazo JL
    Int J Dermatol; 2014 Apr; 53(4):e299-301. PubMed ID: 24262057
    [No Abstract]   [Full Text] [Related]  

  • 11. Antidrug antibodies in psoriasis: a systematic review.
    Hsu L; Snodgrass BT; Armstrong AW
    Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy.
    Shaw CA; Kole LCS; Elewski BE
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e431-e432. PubMed ID: 31220373
    [No Abstract]   [Full Text] [Related]  

  • 13. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
    J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Psoriasis and HIV infection].
    Leal L; Ribera M; Daudén E
    Actas Dermosifiliogr; 2008 Dec; 99(10):753-63. PubMed ID: 19091213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy-resistant folliculitis decalvans and lichen planopilaris successfully treated with adalimumab.
    Kreutzer K; Effendy I
    J Dtsch Dermatol Ges; 2014 Jan; 12(1):74-6. PubMed ID: 24124928
    [No Abstract]   [Full Text] [Related]  

  • 16. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
    Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
    J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab in the treatment of severe paediatric psoriasis.
    Dixit S; Shumack S; Fischer G
    Australas J Dermatol; 2013 May; 54(2):147. PubMed ID: 23581999
    [No Abstract]   [Full Text] [Related]  

  • 20. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.